10-Q: Enzo Biochem Reports Q2 2025 Results: Revenue Declines Amid Strategic Review

Enzo Biochem's Q2 2025 revenue decreased by 14% year-over-year, driven by lower market demand and timing of large order fulfillment, as the company continues to explore strategic alternatives.

Summary

• Enzo Biochem reported a net loss of $1.535 million for the three months ended January 31, 2025, compared to a net loss of $3.061 million for the same period in 2024.
• Revenue for the quarter was $7.334 million, a 14% decrease from $8.553 million in the prior year.
• The company's operating loss was $1.602 million, an improvement from the $2.185 million loss in the same period last year.
• For the six months ended January 31, 2025, Enzo Biochem reported a net loss of $4.911 million, compared to a net loss of $9.677 million for the same period in 2024.
• Revenue for the six-month period was $13.546 million, a 17% decrease from $16.359 million in the prior year.
• The company's operating loss for the six-month period was $5.226 million, an improvement from the $7.655 million loss in the same period last year.
• Cash and cash equivalents decreased to $40.297 million as of January 31, 2025, from $52.371 million as of July 31, 2024.
• The company paid a cash dividend of $0.10 per share on its common stock, totaling $5.324 million, in December 2024.
• Enzo Biochem is exploring strategic alternatives to maximize stockholder value, including potential acquisitions, joint ventures, or a sale of the company.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is experiencing revenue declines, it is also taking steps to improve its financial position and explore strategic alternatives. The improvements in net loss and operating loss are positive signs, but the NYSE listing notice and ongoing legal proceedings are concerns.

Positives

• The net loss for both the three and six months ended January 31, 2025, improved compared to the same periods in 2024.
• The operating loss for both the three and six months ended January 31, 2025, improved compared to the same periods in 2024.
• Selling, general and administrative expenses decreased by $0.5 million for the three months ended January 31, 2025, and $2.6 million for the six months ended January 31, 2025.
• Legal and related expenses decreased by $0.4 million for the three months ended January 31, 2025, and $1.0 million for the six months ended January 31, 2025.
• The company released $5 million of escrowed cash from the Labcorp Asset Purchase Agreement.
• Gross profit margin was positively impacted by a more profitable mix of products sold and cost containment measures.

Negatives

• Revenue decreased by 14% for the three months ended January 31, 2025, and 17% for the six months ended January 31, 2025.
• Cash and cash equivalents decreased by $12.0 million as of January 31, 2025.
• Enzo Biochem received a notice from the NYSE regarding non-compliance with listing standards due to low market capitalization and stock price.
• Interest income, net decreased by $0.4 million for the three months ended January 31, 2025, and $0.8 million for the six months ended January 31, 2025.
• The foreign exchange loss recognized by the Products segment during the three months ended January 31, 2025 was $0.2 million compared to a gain of $0.7 million in the 2024 period, an unfavorable variance of $0.9 million.

Risks

• The company faces declining market demand, primarily in markets outside of the U.S., related to general continued headwinds in the life sciences tools space.
• Enzo Biochem is subject to risks and uncertainties as a result of the ransomware attack, including regulatory scrutiny and class action litigation exposure.
• The company may be delisted from the NYSE if it does not regain compliance with continued listing standards.
• The company is involved in ongoing legal proceedings, including an appraisal action and a whistleblower complaint, which could result in significant costs.
• Unanticipated changes in demand could have a significant impact on the value of inventory and require additional write downs of inventory which would impact results of operations.

Future Outlook

The company continues to explore all strategic alternatives to maximize value for the Company's stockholders, including without limitation, improving the market position and profitability of our services in the marketplace, and enhancing our valuation. We may pursue our goals through organic growth and strategic initiatives. Additionally, we will continue to review information regarding potential acquisitions or joint ventures, and provide information to third parties regarding potential dispositions of assets or business lines, including a potential sale of the Company, from time to time.

Industry Context

The report indicates headwinds in the life sciences tools space, which is impacting Enzo Biochem's revenue. This suggests that other companies in the same industry may be facing similar challenges. The company's strategic review and exploration of alternatives are indicative of a broader trend in the industry to consolidate or restructure in response to market conditions.

Comparison to Industry Standards

• It is difficult to compare Enzo Biochem's results directly to industry standards without knowing the specific sub-segments in which it operates and the performance of its direct competitors.
• However, the report mentions 'headwinds in the life sciences tools space,' suggesting that other companies in this sector may be experiencing similar revenue declines.
• Companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies are major players in the life sciences tools industry, and their financial reports could provide a benchmark for comparison.
• Given Enzo's smaller size, it may be more appropriate to compare it to other smallto mid-sized companies focused on niche areas within the life sciences tools market.
• The company's focus on labeling and detection technologies from DNA to whole cell analysis could be compared to companies specializing in genomics, proteomics, or cell biology research tools.

Legal Proceedings

• Enzo was subject to regulatory inquiry from the New York Attorney General, a joint inquiry from the Connecticut and New Jersey Attorneys General and an inquiry from the Utah Attorney General.
• The matters with the New York, Connecticut and New Jersey Attorneys General are now closed, as they were resolved by agreements with each of the three states effective August 8, 2024.
• Enzo was also subject to regulatory inquiries from the U.S. Department of Health and Human Services Office for Civil Rights (the Office for Civil Rights) regarding the ransomware attack.
• The parties have reached a class-wide settlement agreement in the sum of $7,500 and filed an unopposed motion for preliminary approval with the Court.
• The Court granted the motion and set a final fairness hearing on June 10, 2025.
• The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion was granted by the court.
• The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion remains pending.
• On or about August 21, 2024, the Court dismissed the Companys Second and Third Affirmative Defenses.
• On or about September 19, 2024, the Court granted the Company permission to move for leave to reargue the Courts dismissal decision.
• On or about October 16, 2024, the Company moved for leave to reargue.
• On or about February 20, 2025, the Court issued a decision granting the Companys motion for leave to reargue, and, upon reargument, adhered to its original decision.
• On September 18, 2024, we received an unsealed complaint filed by whistleblowers in the Southern District of New York (SDNY) alleging, among other things, that the Company falsely billed Medicaid and Medicare for COVID-19 tests by utilizing inappropriate diagnostic codes to trigger payments for such tests.
• The court ordered that the matter be stayed until January 15, 2025, so that the parties may explore potential settlement of the matter.
• The Company anticipates filing a motion to dismiss the complaint (the entire case) and, pursuant to the Courts instructions, will be submitting a letter to the court regarding that motion by March 21, 2025.
• The initial conference with the court is scheduled for April 8, 2025.
• At the parties joint request, the arbitration has been stayed while the parties work towards resolving the matter.
• There is currently one case that was originally brought by the Company that is still pending in the Court.
• The claims in that case are stayed.
• On February 6, 2025, the PTO issued a final rejection of the claims (2, 5, 18, 20, and 228) in the ex parte reexamination proceedings.

Stakeholder Impact

• Shareholders: The company is exploring strategic alternatives to maximize value for stockholders.
• Employees: The company has reduced headcount, which may impact employees.
• Customers: The company is facing declining market demand, which may impact product availability or pricing.
• Creditors: The company's cash position has decreased, which may impact its ability to meet its obligations.
• Patients: The ransomware attack impacted the personal data of approximately 2.5 million individuals.

Next Steps

• The company will continue to explore strategic alternatives to maximize stockholder value.
• Enzo Biochem will work to regain compliance with NYSE listing standards.
• The company will continue to vigorously litigate both (i) Petitioners alleged entitlement to dissenting shareholder appraisal rights and (ii) the correct valuation of Petitioners shares.
• The Company anticipates filing a motion to dismiss the complaint (the entire case) and, pursuant to the Courts instructions, will be submitting a letter to the court regarding that motion by March 21, 2025.
• The initial conference with the court is scheduled for April 8, 2025.
• The Court granted the motion and set a final fairness hearing on June 10, 2025.

Key Dates